Author

Francesco Pieri

National Research CouncilORCID 0000-0003-4456-8581Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Assay:imaging· 1

Frequent Co-Authors

Carlo GambaccianiiD· 2 shared Chiara Maria MazzantiiD· 2 shared Francesca LessiiD· 2 shared Francesco PasqualettiiD· 2 shared Gianmarco FerriiD· 2 shared Mariangela MorelliiD· 2 shared Michele Menicagli· 2 shared Orazio Santo SantonocitoiD· 2 shared

Activity by Year

2022-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Carlo GambaccianiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 20, 2026

From Single-Cell Emergent Behaviors to Clinical Outcome: PTEN-driven Migratory Efficiency as a Potential New Vulnerability in Glioblastoma

Mariangela Morelli, Gianmarco Ferri, Francesca Lessi…·Chiara Maria Mazzanti

This study identifies PTEN gain-of-function mutations as linked to increased migratory efficiency in glioblastoma cells, correlating with poorer patient survival.

DOI 10.64898/2026.03.18.712310

humanbulk RNA-seq

𝕏 PostBluesky

Molecular BiologyFrontiers in OncologyPeer-reviewedSep 5, 2022

Metabolic-imaging of human glioblastoma explants: a new precision-medicine model to predict tumor treatment response early

Mariangela Morelli, Francesca Lessi, Serena Barachini…·Chiara Maria Mazzanti

This paper develops a functional precision medicine approach using metabolic imaging to predict glioblastoma treatment response early in ex-vivo organoids, identifying responder and non-responder groups and a new molecular signature.

39 citationstop 4%

humanimaging

𝕏 PostBluesky